亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

HIV Therapeutics

技術優勢
Firstwell-validated compound known to boost A3G
詳細技術說明
Novel small molecule that boosts the innate immune response against viral infection#biomedical #infectiousdisease #HIV
*Abstract

Northwestern researchers have identified a lead compound that can be further developed into a drug for boosting the immune response to HIV and other viral infections. One way that human cells respond to infection by HIV is to deploy several proteins to interfere with viral replication. A3G and A3F are two such proteins, but HIV virus has evolved an attack mechanism that can degrade them rendering cells more vulnerable to infection. Dr. Schiltz and colleagues have identified a compound that can stimulate A3G levels in cells, which provides cells with increased protection against infection. This compound could also be potentially used to develop topical agents for prevention of HIV acquisition across the mucosal membranes or systemic therapies that would limit establishment of latent reservoirs.

*Inventors
Gary Schiltz*Chisu SongRichard D’Aquila
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備